Internship

Co-Op – Discovery Biology: Stromal Immunology

Spring 2025

Confirmed live in the last 24 hours

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Boston, MA, USA

Onsite presence is essential for collaboration and productivity.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • An academic background in molecular and cell biology and/or immunology with a strong academic record (≥ 3.5 GPA); working knowledge of key molecular and immunology concepts.
  • Training in basic molecular biology techniques and cell culture; at least three semesters of laboratory course work and/or research experience.
  • Prior laboratory experience in industry or academic setting is desired.
  • Experience in cell-based assay development and CRISPR-Cas9 editing is a plus.
  • Excellent communication skills and a team-oriented mindset are required.
  • Enthusiasm for science and strong drive to learn.
Responsibilities
  • Under guidance, design and execute CRISPR-based genome editing and cell-based assays to advance target candidate validation for various programs in the stromal immunology space.
  • Analyze, interpret, and present data, perform QC and troubleshooting.
  • Maintain detailed written record of experiments and results, and promptly communicate key information to stakeholders.
  • Continuously educate yourself on key stromal immunology concepts and processes relevant to the project, as well as laboratory techniques.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing access to effective and affordable healthcare solutions.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's involvement in Nobel Prize-winning immunology research underscores its leadership in groundbreaking scientific advancements.
  • The robust pipeline of molecular glues and other innovative therapies promises significant revenue growth and market expansion.
  • Recognition in the Dow Jones Sustainability Index North America highlights BMS's commitment to corporate responsibility and sustainability, enhancing its reputation and stakeholder trust.

What critics are saying

  • The termination of strategic collaborations, such as with Eisai, could impact BMS's ability to bring new therapies to market efficiently.
  • Ongoing layoffs and restructuring efforts may lead to decreased employee morale and potential disruptions in operations.

What makes Bristol-Myers Squibb unique

  • Bristol Myers Squibb's dual focus on innovative and generic medicines allows it to cater to a broad spectrum of healthcare needs, unlike competitors who may focus solely on one area.
  • Their commitment to sustainability and ESG goals sets them apart in the biopharmaceutical industry, appealing to socially conscious investors and stakeholders.
  • BMS's extensive R&D investment in oncology, immunology, and cardiovascular diseases positions it as a leader in developing cutting-edge treatments for serious diseases.

Help us improve and share your feedback! Did you find this helpful?